Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Callegaro

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Science Translational Medicine|November 12, 2020
Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signatureLaurane De Mot, Viviane Bechtold, Vanesa Bol, et al.
NPJ Vaccines|March 8, 2024
Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccineValentino Conti, Omar Rossi, Kristen A Clarkson, et al.
Breast Cancer Research and Treatment|March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumorsSteven A Limentani, Mario Campone, Thierry Dorval, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Science Translational Medicine|November 12, 2020
Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signatureLaurane De Mot, Viviane Bechtold, Vanesa Bol, et al.
NPJ Vaccines|March 8, 2024
Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccineValentino Conti, Omar Rossi, Kristen A Clarkson, et al.
Breast Cancer Research and Treatment|March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumorsSteven A Limentani, Mario Campone, Thierry Dorval, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 5